Results 31 to 40 of about 115,888 (246)
Development of an efficient mice model of cancer‐associated cardiac cachexia
This work establishes a preclinical framework for targeting ubiquitin pathways to mitigate the morbidity of cancer‐related cardiopathy. Our integrated approach delineates a hierarchical progression from subcellular dysfunction to macroscopic cardiac deterioration. These findings mechanistically link tumor‐induced cachexia to cardiac dysfunction through
Shijie Xiong +9 more
wiley +1 more source
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source
Answer: Never skip a beat: pacing-induced polymorphic ventricular tachycardia following inferior myocardial infarction [PDF]
Lung En Teng, Sean Tan, Roshan Prakash
openalex +1 more source
Biomaterial design strategies for enhancing mitochondrial transplantation therapy
Biomaterials to facilitate mitochondrial transplantation therapy: biomaterials as barriers to protect mitochondria from pathophysiological microenvironments, like osmotic stress caused by the excessive concentration of calcium ion, reactive oxygen species, and advanced glycation end products; biomaterials integrating with biochemical cues to improve ...
Shaoyang Kang +12 more
wiley +1 more source
Applying DanGer Shock Eligibility Criteria to a Real‐World Cohort of Cardiogenic Shock Patients
ABSTRACT Background The DanGer Shock trial investigated the effects of adding a microaxial flow pump to guideline‐recommended therapy in patients with ST‐elevation myocardial infarction (STEMI)‐related cardiogenic shock (CS), finding a lower all‐cause mortality at 180 days in the intervention group.
Raffaela Miriam Planka +14 more
wiley +1 more source
SEARCH OF THE STRESS INDUSED VENTRICULAR TACHICARDIA REASONS — THE METABOLIC THERAPY OPPORTUNITIES
A clinical case of a 56-year-old man is presented in which only ventricular tachycardia without clinical and ECG criteria of myocardial ischemia is recorded on the exercise test. The ventricular tachycardia was the only reason for stopping the test. This
T. V. Treshkur +2 more
doaj +1 more source
33 year old gentleman has undergone an electrophysiology study for recurrent paroxysmal palpitation. During one of the episodes of palpitation a regular narrow QRS tachycardia was documented which has terminated with intravenous adenosine.
Krishna Kumar Mohanan Nair +5 more
doaj +1 more source
ABSTRACT Alcohol septal ablation is a well‐established treatment method for patients with hypertrophic cardiomyopathy. We present a case report of a patient with transposition of the great arteries (TGA) after a Mustard procedure, who developed significant right ventricular outflow tract obstruction (RVOTO), functionally resembling subaortic stenosis ...
Vera Osberghaus +6 more
wiley +1 more source
Potential adverse drug events can be signaled in Clinical Decision Support Systems (CDSSs). This study validated a Swedish CDSS (Janusmed Risk Profile) by investigating associations between calculated risk classifications of drugs with QT‐prolonging potential and registered related clinical outcomes.
Ola Nordqvist +6 more
wiley +1 more source
Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu +3 more
wiley +1 more source

